Gyrolab Generic Anti-AAV Kit

Screening for pre-existing antibodies against adeno-associated virus (AAV) is vital in AAV vector-based gene therapy development as it helps predict potential immune reactions, tailor therapeutic strategies to individual patients, and refine clinical trial designs allowing for better patient stratification and selection. Gyros Protein Technologies presents the Gyrolab^® Generic Anti-AAV Kit, which enables the detection of anti-AAV antibodies in human and cynomolgus monkey matrices. The kit eliminates the need for AAV serotype-specific assay development, has a ready-to-use format that offers fast and reliable results, reducing variability and manual errors, and automates total binding anti-AAV antibodies detection with a 90-minute run time and minimal capsid consumption.